The biology of interleukin-2

Annual Review of Immunology

Volumn 26, Issue , 2008, Pages 453-479

  Malek, Thomas R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

IL 2; Immune memory; Immune tolerance; T effector cell; T regulatory cell

Indexed keywords

INTERLEUKIN 2;

AUTOIMMUNITY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; AUTOIMMUNITY; HUMANS; IMMUNITY; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY;

EID: 41949097030     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.26.021607.090357     Document Type: Review

References (187)

1. Morgan DA, Ruscetti FW, Gallo R. 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007-8
2. Gillis S, Smith KA. 1977. Long-term culture of tumour-specific cytotoxic T cells. Nature 268:154-56
3. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, et al. 1983. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302:305-10
4. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253-61
5. + T cells. Eur. J. Immunol. 25:3053-59
6. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. 1995. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521-30
7. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, et al. 1995. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 268:1472-76
8. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-62
9. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. 1997. Regulatory CD4 T cells: expression of IL-2Rα chain, resistance to clonal deletion and IL-2 dependency. Int. Immunol. 10:371-78
10. Suzuki H, Zhou YW, Kato M, Mak TW, Nakashima I. 1999. Normal regulatory α/β T cells effectively eliminate abnormally activated T cells lacking the interleukin 2 receptor β in vivo. J. Exp. Med. 190:1561-72
11. + T cells: evidence for two distinct regulatory mechanisms. Eur. J. Immunol. 31:1637-45
12. Klebb G, Autenrieth IB, Haber H, Gillert E, Sadlack B, et al. 1996. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin. Immunol. Immunopathol. 81:282-86
13. + regulatory T cell function. J. Exp. Med. 196:851-57
14. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. 2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17:167-78
15. + T cell numbers. J. Immunol. 169:4850-60
16. Kundig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I. 1993. Immune responses in interleukin-2-deficient mice. Science 262:1059-61
17. Bachmann MF, Schorle H, Kuhn R, Muller W, Hengartner H, et al. 1995. Antiviral immune responses in mice deficient for both interleukin-2 and interleukin-4. J. Virol. 69:4842-46
18. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. 1995. IL-2 knockout recipient mice reject islet cell allografts. J. Immunol. 155:489-98
19. Malek TR, Bayer AL. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4:665-74
20. + memory T cells. Nature 441:890-93
21. + T cell responses in acute and chronic viral infections. Eur. J. Immunol. 37:1502-12
22. Nelson BH, Willerford DM. 1998. Biology of the interleukin-2 receptor. Adv. Immunol. 70:1-81
23. Waldmann TA, Dubois S, Tagaya Y. 2001. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14:105-10
24. Gaffen SL. 2001. Signaling domains of the interleukin 2 receptor. Cytokine 14:63-77
25. Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, et al. 2001. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2:882-88
26. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201:723-35
27. Yui MA, Hernandez-Hoyos G, Rothenberg EV. 2001. A new regulatory region of the IL-2 locus that confers position-independent transgene expression. J. Immunol. 166:1730-39
28. Yui MA, Sharp LL, Havran WL, Rothenberg EV. 2004. Preferential activation of an IL-2 regulatory sequence transgene in TCR γδ and NKT cells: subset-specific differences in IL-2 regulation. J. Immunol. 172:4691-99
29. + regulatory T cells? Eur. J. Immunol. 35:1193-200
30. Serfling E, Avots A, Neumann M. 1995. The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim. Biophys. Acta 1263:181-200
31. Jain J, Loh C, Rao A. 1995. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 7:333-42
32. Shaw J, Meerovitch K, Bleackley RC, Paetkau V. 1988. Mechanisms regulating the level of IL-2 mRNA in T lymphocytes. J. Immunol. 140:2243-48
33. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB. 1989. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339-43
34. Fraser JD, Irving BA, Crabtree GR, Weiss A. 1991. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251:313-16
35. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, et al. 2007. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446:685-89
36. Brombacher F, Schafer T, Weissenstein U, Tschopp C, Andersen E, et al. 1994. IL-2 promoter-driven lacZ expression as a monitoring tool for IL-2 expression in primary T cells of transgenic mice. Int. Immunol. 6:189-97
37. Reed WA, Elzer PH, Enright FM, Jaynes JM, Morrey JD, White KL. 1997. Interleukin 2 promoter/enhancer controlled expression of a synthetic cecropin-class lytic peptide in transgenic mice and subsequent resistance to Brucella abortus. Transgenic Res. 6:337-47
38. Minasi LE, Kamogawa Y, Carding S, Bottomly K, Flavell RA. 1993. The selective ablation of interleukin 2-producing cells isolated from transgenic mice. J. Exp. Med. 177:1451-59
39. Barton K, Muthusamy N, Chanyangam M, Fischer C, Clendenin C, Leiden JM. 1996. Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature 379:81-85
40. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, et al. 2005. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 115:996-1005
41. Bodor J, Bodorova J, Gress RE. 2000. Suppression of T cell function: a potential role for transcriptional repressor ICER. J. Leukoc. Biol. 67:774-79
42. Yasui DH, Genetta T, Kadesch T, Williams TM, Swain SL, et al. 1998. Transcriptional repression of the IL-2 gene in Th cells by ZEB. J. Immunol. 160:4433-40
43. Williams TM, Moolten D, Burlein J, Romano J, Bhaerman R, et al. 1991. Identification of a zinc finger protein that inhibits IL-2 gene expression. Science 254:1791-94
44. Hwang ES, Hong JH, Glimcher LH. 2005. IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508. J. Exp. Med. 202:1289-300
45. Villarino AV, Tato CM, Stumhofer JS, Yao Z, Cui YK, et al. 2007. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J. Exp. Med. 204:65-71
46. Gong D, Malek TR. 2007. Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J. Immunol. 178:242-52
47. Martins GA, Cimmino L, Shapiro-Shelef M, Szabolcs M, Herron A, et al. 2006. Transcriptional repressor Blimp-1 regulates T cell homeostasis and function. Nat. Immunol. 7:457-65
48. Kallies A, Hawkins ED, Belz GT, Metcalf D, Hommel M, et al. 2006. Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance. Nat. Immunol. 7:466-74
49. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. 2006. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc. Natl. Acad. Sci. USA 103:2788-93
50. Ricken M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. 2005. The structure of interleukin-2 complexed with its α receptor. Science 308:1477-80
51. Yu A, Olosz F, Choi C, Malek T. 2000. Efficient internalization of IL-2 depends upon the distal portion of the cytoplasmic tail of the IL-2R γc subunit and a lymphoid cell environment. J. Immunol. 165:2556-62
52. Yu CL, Burakoff SJ. 1997. Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation. J. Biol. Chem. 272:14017-20
53. Hemar A, Subtil A, Lieb M, Morelon E, Hellio R. 1995. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor α, β, and γ chains. J. Cell Biol. 129:55-64
54. Yu A, Malek TR. 2001. The proteasome regulates receptor-mediated endocytosis of interleukin-2. J. Biol. Chem. 276:381-85
55. Cantrell DA, Smith KA. 1984. The interleukin-2 T-cell system: a new cell growth model. Science 224:1312-16
56. Leonard WJ. 2001. Cytokines and immunodeficiency diseases. Nat. Rev. Immunol. 1:200-8
57. Ma A, Koka R, Burkett P. 2006. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol. 24:657-79
58. Kim HP, Imbert J, Leonard WJ. 2006. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 17:349-66
59. Kim HP, Kim BG, Letterio J, Leonard WJ. 2005. Smad-dependent cooperative regulation of interleukin 2 receptor α chain gene expression by T cell receptor and transforming growth factor-β. J. Biol. Chem. 280:34042-47
60. Rogers WO, Weaver CT, Kraus LA, Li J, Li L, Bucy RP. 1997. Visualization of antigen-specific T cell activation and cytokine expression in vivo. J. Immunol. 158:649-57
61. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6:1142-51
62. Yang-Snyder JA, Rothenberg EV. 1998. Spontaneous expression of interleukin-2 in vivo in specific tissues of young mice. Dev. Immunol. 5:223-45
63. De Creus A, Van Beneden K, Stevenaert F, Debacker V, Plum J, Leclercq G. 2002. Developmental and functional defects of thymic and epidermal Vγ3 cells in IL-15-deficient and IFN regulatory factor-1-deficient mice. J. Immunol. 168:6486-93
64. Ye SK, Maki K, Lee HC, Ito A, Kawai K, et al. 2001. Differential roles of cytokine receptors in the development of epidermal γδ T cells. J. Immunol. 167:1929-34
65. Kawai K, Suzuki H, Tomiyama K, Minagawa M, Mak TW, Ohashi PS. 1998. Requirement of the IL-2 receptor β chain for the development of Vγ3 dendritic epidermal T cells. J. Invest. Dermatol. 110:961-65
66. -/- mice: roles for both IL-2 and IL-15 in CD8αα IEL development. J. Immunol. 163:5906-12
67. Fontenot JD, Dooley JL, Farr AG, Rudensky AY. 2005. Developmental regulation of Foxp3 expression during ontogeny. J. Exp. Med. 202:901-6
68. + regulatory T cells in human thymus. Nature 436:1181-85
69. Khoruts A, Mondino A, Pape KA, Reiner SL, Jenkins MK. 1998. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J. Exp. Med. 187:225-36
70. + T cells in vivo is rapid, transient, and influenced by TCR-specific competition. J. Immunol. 172:6136-43
71. D'Souza WN, Lefrancois L. 2004. Frontline: an in-depth evaluation of the production of IL-2 by antigen-specific CD8 T cells in vivo. Eur. J. Immunol. 34:2977-85
72. Huse M, Lillemeier BF, Kuhns MS, Chen DS, Davis MM. 2006. T cells use two directionally distinct pathways for cytokine secretion. Nat. Immunol. 7:247-55
73. 3+ regulatory T cells. J. Immunol. 178:280-90
74. Hori S, Nomura T, Sakaguchi S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-61
75. + regulatory T cells. Nat. Immunol. 4:330-36
76. + regulatory T cells at the single-cell level. Eur. J. Immunol. 35:1681-91
77. 3+ T regulatory cells. J. Immunol. 178:4062-71
78. Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, et al. 2006. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J. Immunol. 176:5255-66
79. + regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. 6:1152-59
80. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. 2005. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J. Exp. Med. 202:1375-86
81. 3+ T regulatory cells suppress autoimmunity while establishing transplantation tolerance. J. Immunol. 176:7149-53
82. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, et al. 2006. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 103:6659-64
83. Mantel PY, Ouaked N, Ruckert B, Karagiannidis C, Welz R, et al. 2006. Molecular mechanisms underlying FOXP3 induction in human T cells. J. Immunol. 176:3593-602
84. + T cells. Eur. J. Immunol. 37:129-38
85. Lyons PA, Armitage N, Argentina F, Denny P, Hill NJ, et al. 2000. Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping. Genome Res. 10:446-53
86. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, et al. 2007. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 39:329-37
87. Sharfe N, Dadi HK, Shahar M, Roifman CM. 1997. Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor. Proc. Natl. Acad. Sci. USA 94:3168-71
88. Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. 2007. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119:482-87
89. Aoki CA, Roifman CM, Lian ZX, Bowlus CL, Norman GL, et al. 2006. IL-2 receptor α deficiency and features of primary biliary cirrhosis. J. Autoimmun. 27:50-53
90. Roifman CM. 2000. Human IL-2 receptor α chain deficiency. Pediatr. Res. 48:6-11
91. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 447:661-78
92. Snow JW, Abraham N, Ma MC, Herndier BG, Pastuszak AW, Goldsmith MA. 2003. Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J. Immunol. 171:5042-50
93. + memory T cells. J. Immunol. 171:5853-64
94. + regulatory T cell homeostasis and the maintenance of self-tolerance. J. Immunol. 171:3435-41
95. Peffault de Latour R, Dujardin HC, Mishellany F, Burlen-Defranoux O, Zuber J, et al. 2006. Ontogeny, function, and peripheral homeostasis of regulatory T cells in the absence of interleukin-7. Blood 108:2300-6
96. high T cells in human STAT5b deficiency. J. Immunol. 177:2770-74
97. Liston A, Rudensky AY. 2007. Thymic development and peripheral homeostasis of regulatory T cells. Curr. Opin. Immunol. 19:176-85
98. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431-40
99. + regulatory T cells. J. Immunol. 171:3348-52
100. Tai X, Cowan M, Feigenbaum L, Singer A. 2005. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 6:152-62
101. Liston A, Siggs OM, Goodnow CC. 2007. Tracing the action of IL-2 in tolerance to islet-specific antigen. Immunol. Cell Biol. 85:338-42
102. Malek TR, Porter BO, Codias EK, Scibelli P, Yu A. 2000. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J. Immunol. 164:2905-14
103. Wan YY, Flavell RA. 2007. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445:766-70
104. + T regulatory cell development during the neonatal period. J. Exp. Med. 201:769-77
105. + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108:1571-79
106. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, et al. 2007. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109:4368-75
107. + T regulatory cells. J. Immunol. 177:5115-21
108. + suppressor T cells in vivo. Nat. Immunol. 3:33-41
109. Min B, McHugh R, Sempowski GD, Mackall C, Foucras G, Paul WE. 2003. Neonates support lymphopenia-induced proliferation. Immunity 18:131-40
110. + regulatory T cells. In Regulatory T Cells and Clinical Applications, ed. S Jiang, RI Lechler. New York: Springer. In press
111. Vlad G, Ho EK, Vasilescu ER, Fan J, Liu Z, et al. 2007. Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl. Immunol. 18:13-21
112. + regulatory T-cell pool is present in renal transplant recipients. Am. J. Transplant. 7:249-55
113. Waldmann TA. 2007. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 26:3699-703
114. + T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 166:3008-18
115. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287-96
116. + T lymphocytes. J. Immunol. 174:155-63
117. + T cells for IL-2 and exploit it for the induction of IL-10 production. Int. Immunol. 17:279-88
118. + T cell suppressor function. J. Immunol. 172:6519-23
119. + regulatory T cell function. Eur. J. Immunol. 34:2480-88
120. Soper DM, Kasprowicz DJ, Ziegler SF. 2007. IL-2Rβ links IL-2R signaling with Foxp3 expression. Eur. J. Immunol. 37:1817-26
121. + T cell suppressor function. Eur. J. Immunol. 34:366-76
122. + regulatory T cells is indexed to the number of IL-2-producing cells. J. Immunol. 177:192-200
123. Jaeckel E, Kretschmer K, Apostolou I, von Boehmer H. 2006. Instruction of Treg commitment in peripheral T cells is suited to reverse autoimmunity. Semin. Immunol. 18:89-92
124. - T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172:5149-53
125. + regulatory T cells by TGFβ induction of transcription factor Foxp3. J. Exp. Med. 198:1875-86
126. - cells to develop suppressive activity: the role of IL-2, TGFβ, and IL-10. J. Immunol. 172:5213-21
127. + T regulatory cells. J. Immunol. 178:4022-26
128. + regulatory T cells and for expansion of these cells. J. Immunol. 178:2018-27
129. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-38
130. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, et al. 2007. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445:771-75
131. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. 2006. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179-89
132. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, et al. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26:371-81
133. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, et al. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178:6730-33
134. + regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J. Immunol. 173:4994-5001
135. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, et al. 2006. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126:375-87
136. Lin W, Haribhai D, Relland LM, Truong N, Carlson MR, et al. 2007. Regulatory T cell development in the absence of functional Foxp3. Nat. Immunol. 8:359-68
137. Williams LM, Rudensky AY. 2007. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8:277-84
138. Hwang KW, Sweatt WB, Mashayekhi M, Palucki DA, Sattar H, et al. 2004. Transgenic expression of CTLA-4 controls lymphoproliferation in IL-2-deficient mice. J. Immunol. 173:5415-24
139. Carrier Y, Yuan J, Kuchroo VK, Weiner HL. 2007. Th3 cells in peripheral tolerance. II. TGF-β-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J. Immunol. 178:172-78
140. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540-47
141. + T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. USA 99:3001-6
142. + T cells increases tbe size of the acute antiviral response and of the resulting memory T cell pool. J. Immunol. 169:4990-97
143. Cousens LP, Orange JS, Biron CA. 1995. Endogenous IL-2 contributes to T cell expansion and IFN-γ production during lymphocytic choriomeningitis virus infection. J. Immunol. 155:5690-99
144. + T cell interactions in IFN-γ and IL-4 responses to viral infections: requirements for IL-2. J. Immunol. 160:5007-17
145. Leung DT, Morefield S, Willerford DM. 2000. Regulation of lymphoid homeostasis by IL-2 receptor signals in vivo. J. Immunol. 164:3527-34
146. + T cell memory by promoting the generation of IL-7Rα-expressing cells. J. Exp. Med. 204:547-57
147. Krämer S, Mamalaki C, Schimpl A, Kioussis D, Hünig T. 1994. Thymic selection and peptide-induced activation of T cell receptor-transgenic CD8 T cells in interleukin-2-deficient mice. Eur. J. Immunol. 24:2317-22
148. + memory T cells. J. Immunol. 165:3031-36
149. D'Souza WN, Schluns KS, Masopust D, Lefrancois L. 2002. Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. J. Immunol. 168:5566-72
150. D'Souza WN, Lefrancois L. 2003. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J. Immunol. 171:5727-35
151. + T cells in the absence of IL-2/15 receptor β-chain expression or STAT5 activation. J. Immunol. 173:3131-39
152. Yu A, Zhou J, Marten N, Bergmann CC, Mammolenti M, et al. 2003. Efficient induction of primary and secondary T cell-dependent immune responses in vivo in the absence of functional IL-2 and IL-15 receptors. J. Immunol. 170:236-42
153. Jin H, Gong D, Adeegbe D, Bayer AL, Rolle C, et al. 2006. Quantitative assessment concerning the contribution of IL-2Rβ for superantigen-mediated T cell responses in vivo. Int. Immunol. 18:565-72
154. Lenardo MJ. 1991. Interleukin-2 programs αβ T lymphocytes for apoptosis. Nature 353:858-61
155. Malek TR, Yu A, Scibelli P, Lichtenheld MG, Codias EK. 2001. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J. Immunol. 166:1675-83
156. + T cell survival but not antigen proliferation. Nat. Immunol. 1:54-58
157. + T cell without effector differentiation. Proc. Natl. Acad. Sci. USA 103:19454-59
158. Dooms H, Kahn E, Knoechel B, Abbas AK. 2004. IL-2 induces a competitive survival advantage in T lymphocytes. J. Immunol. 172:5973-79
159. Seddon B, Tomlinson P, Zamoyska R. 2003. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat. Immunol. 4:680-86
160. Li J, Huston G, Swain SL. 2003. IL-7 promotes the transition of CD4 effectors to persistent memory cells. J. Exp. Med. 198:1807-15
161. Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD, Bradley LM. 2003. Interleukin 7 regulates the survival and generation of memory CD4 cells. J. Exp. Med. 198:1797-806
162. Williams MA, Bevan MJ. 2007. Effector and memory CTL differentiation. Annu. Rev. Immunol. 25:171-92
163. Wong P, Pamer EG. 2004. Disparate in vitro and in vivo requirements for IL-2 during antigen-independent CD8 T cell expansion. J. Immunol. 172:2171-76
164. Spierings DC, Lemmens EE, Grewal K, Schoenberger SP, Green DR. 2006. Duration of CTL activation regulates IL-2 production required for autonomous clonal expansion. Eur. J. Immunol. 36:1707-17
165. + regulatory T cells. Nat. Med. 11:1238-43
166. + regulatory T cells in cancer patients. Blood 107:2409-14
167. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24:1169-77
168. van Dervliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, et al. 2007. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res. 13:2100-8
169. bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103:5941-46
170. bright regulatory NK cells in patients with active uveitis. J. Immunol. 174:5187-91
171. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, et al. 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 91:123-32
172. Tang Q, Bluestone JA. 2006. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 212:217-37
173. + cells. Semin. Immunol. 18:78-88
174. + Tregs. J. Clin. Invest. 116:2521-31
175. + regulatory T cells. J. Immunol. 172:5287-96
176. + natural regulatory T cells revealed by DNA microarray analysis. Int. Immunol. 18:1197-209
177. Lali FV, Crawley J, McCulloch DA, Foxwell BM. 2004. A late, prolonged activation of the phosphatidylinositol 3-kinase pathway is required for T cell proliferation. J. Immunol. 172:3527-34
178. + regulatory T cells. Blood 105:4743-48
179. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177:8338-47
180. + T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur. J. Immunol. 36:2139-49
181. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. 2006. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311:1924-27
182. Kneitz B, Herrmann T, Yonehara S, Schimpl A. 1995. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur. J. Immunol. 25:2572-77
183. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. 1998. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J. Immunol. 161:1659-63
184. Li XC, Roy-Chaudhury P, Hancock WW, Manfro R, Zand MS, et al. 1998. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. J. Immunol. 161:890-96
185. + T cells protect IL-2 receptor α-deficient mice from systemic infection with herpes simplex virus type 2. J. Immunol. 165:4552-60
186. Suzuki H, Hayakawa A, Bouchard D, Nakashima I, Mak TW. 1997. Normal thymic selection, superantigen-induced deletion and Fas-mediated apoptosis of T cells in IL-2 receptor β-chain deficient mice. Int. Immmunol. 9:1367-74
187. Nishimura H, Tagaya M, Tsunobuchi H, Suzuki H, Nakashima I, Yoshikai Y. 2001. Mice lacking interleukin-2 (IL-2)/IL-15 receptor β chain are susceptible to infection with avirulent Salmonella enterica subsp. enterica serovar choleraesuis but mice lacking IL-2 are resistant. Infect. Immun. 69:1226-29